Philips has received FDA clearance for Spectral CT 7500 RT, the first CT scanner to combine spectral and 4D imaging for radiation therapy.

The detector-based spectral CT system allows clinicians to refine cancer treatment planning by visualizing and characterizing tumors more precisely, while sparing surrounding healthy tissue. With the addition of respiratory-gated spectral imaging, radiation oncologists can capture both conventional and spectral CT data in a single scan.

“Tumor delineation, beam attenuation, and respiratory motion are critical factors in radiotherapy planning,” said Dan Xu, global business leader of CT at Philips. "The spectral information provided by Spectral CT 7500 RT enhances tissue characterization, enabling wider access to highly personalized and precisely targeted treatment for more patients without adding extra steps to current radiotherapy workflows."
A key advantage of the Spectral CT 7500 RT is its ability to produce proton stopping-power ratio (SPR) maps with more than 50% greater accuracy than conventional CT scans. This precision, facilitated by direct electron density (ED) readings with under 1% deviation, allows radiation oncologists to better calculate treatment dosages.

The Spectral CT 7500 RT will be showcased at the upcoming RSNA 2024 conference.

CT Homepage